Why Acrivon Therapeutics, Inc.’s (ACRV) Stock Is Up 6.15%
As of Monday, August 17, Acrivon Therapeutics, Inc.’s ACRV share price has surged by 6.15%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Commentary & Analysis
Why Acrivon Therapeutics, Inc.’s (ACRV) Stock Is Up 5.14%
As of Friday, August 14, Acrivon Therapeutics, Inc.’s ACRV share price has surged by 5.14%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Acrivon Therapeutics, Inc.’s (ACRV) Stock Is Up 5.12%
As of Wednesday, August 05, Acrivon Therapeutics, Inc.’s ACRV share price has surged by 5.12%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Acrivon Therapeutics, Inc.’s (ACRV) Stock Is Up 5.92%
As of Friday, July 31, Acrivon Therapeutics, Inc.’s ACRV share price has surged by 5.92%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Acrivon Therapeutics, Inc.’s (ACRV) Stock Is Down 7.14%
As of Wednesday, July 29, Acrivon Therapeutics, Inc.’s ACRV share price has dipped by 7.14%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | ACRV | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $94.3 | $286.3 | 21% |
|
| Shares Out (Mil) | 41.8 | 54.2 | 43% |
|
| Institutional Ownership | 79.6% | 92.8% | 49% |
|
| Float (Mil) | 25.6 | 39.7 | 33% |
|
| Beta | 1.86 | 0.94 | 90% |
|
| Avg Daily Volume (000s) | 510 | 534 | 58% |
|
| Price Change (52-week) |
69.2% | 58.7% | 85% |
|
| Growth | ACRV | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (71.2%) | (10.1%) | 4% |
|
| EPS (5yr) | 11.4% | 16.0% | 49 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (4.4%) | (15.6%) | 61% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 6 | 7 | |
| Current EPS | ($0.448) | ($1.817) | ($1.729) | |
| Month Ago EPS | ($0.521) | ($2.066) | ($1.950) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.521) | ($2.066) | ($1.950) | |
| Year/Year Chg | 4.4% | (10.2%) | (9.8%) | |
| Financials | ACRV | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($74) | ($43) | 13% |
|
| EPS (TTM) | ($1.881) | ($1.400) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($63) | ($31) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($1) | $2 | 41% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 17% |
|
| Enterprise Value (Q1) (Mil) | $0 | $160 | 3% |
|
| Valuation | ACRV | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.09 | 2.77 | 25% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ACRV | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (57.6%) | (47.3%) | 10% |
|
| ROE | (64.6%) | (55.0%) | 13% |
|
| Liabilities to Assets | 12.5% | 29.6% | 8% |
|
| F-Score | 2 | 2 | 7% |
|
Passing Stock Screens
As of 8/19/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Top 30 Up
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 21.5% |
| +/- S&P 500: | +14.0 |
FACTOR STRATEGY
Est Rev: Up 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 22.7% |
| +/- S&P 500: | +15.2 |
